Conditions: Waldenstrom's Macroglobulinemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.

Detailed description:
Patients who had no evidence of disease progression or toxicity while participating in study 8400-401 (NCT02092909) will continue to receive IMO-8400 until disease progression, adverse event or the investigator deems the goals of extended treatment with IMO-8400 have been met.

Arms:
arm 1: Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401

Interventions: intervention 1: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
Intervention descriptions: intervention 1: IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401

Protocol document: